Unterrainer, M. and Fleischmann, D. F. and Vettermann, F. and Ruf, V and Kaiser, L. and Nelwan, D. and Lindner, S. and Brendel, M. and Wenter, V and Stoecklein, S. and Herms, J. and Milenkovic, V. M. and Rupprecht, R. and Tonn, J. C. and Belka, C. and Bartenstein, P. and Niyazi, M. and Albert, N. L. (2020) TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative F-18-GE-180 PET study. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47 (6). pp. 1368-1380. ISSN 1619-7070, 1619-7089
Full text not available from this repository. (Request a copy)Abstract
Background The 18-kDa translocator protein (TSPO) is overexpressed in brain tumours and represents an interesting target for glioma imaging. F-18-GE-180, a novel TSPO ligand, has shown improved binding affinity and a high target-to-background contrast in patients with glioblastoma. However, the association of uptake characteristics on TSPO PET using F-18-GE-180 with the histological WHO grade and molecular genetic features so far remains unknown and was evaluated in the current study. Methods Fifty-eight patients with histologically validated glioma at initial diagnosis or recurrence were included. All patients underwent F-18-GE-180 PET, and the maximal and mean tumour-to-background ratios (TBRmax, TBRmean) as well as the PET volume were assessed. On MRI, presence/absence of contrast enhancement was evaluated. Imaging characteristics were correlated with neuropathological parameters (i.e. WHO grade, isocitrate dehydrogenase (IDH) mutation, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and telomerase reverse transcriptase (TERT) promoter mutation). Results Six of 58 patients presented with WHO grade II, 16/58 grade III and 36/58 grade IV gliomas. An (IDH) mutation was found in 19/58 cases, and 39/58 were classified as IDH-wild type. High F-18-GE-180-uptake was observed in all but 4 cases (being WHO grade II glioma, IDH-mutant). A high association of F-18-GE-180-uptake and WHO grades was seen: WHO grade IV gliomas showed the highest uptake intensity compared with grades III and II gliomas (median TBRmax 5.15 (2.59-8.95) vs. 3.63 (1.85-7.64) vs. 1.63 (1.50-3.43), p < 0.001); this association with WHO grades persisted within the IDH-wild-type and IDH-mutant subgroup analyses (p < 0.05). Uptake intensity was also associated with the IDH mutational status with a trend towards higher F-18-GE-180-uptake in IDH-wild-type gliomas in the overall group (median TBRmax 4.67 (1.56-8.95) vs. 3.60 (1.50-7.64), p = 0.083); however, within each WHO grade, no differences were found (e.g. median TBRmax in WHO grade III glioma 4.05 (1.85-5.39) vs. 3.36 (2.32-7.64), p = 1.000). No association was found between uptake intensity and MGMT or TERT (p > 0.05 each). Conclusion Uptake characteristics on F-18-GE-180 PET are highly associated with the histological WHO grades, with the highest F-18-GE-180 uptake in WHO grade IV glioblastomas and a PET-positive rate of 100% among the investigated high-grade gliomas. Conversely, all TSPO-negative cases were WHO grade II gliomas. The observed association of F-18-GE-180 uptake and the IDH mutational status seems to be related to the high inter-correlation of the IDH mutational status and the WHO grades.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRANSLOCATOR PROTEIN; BENZODIAZEPINE-RECEPTOR; STEREOTACTIC BIOPSY; HUMAN ASTROCYTOMAS; EXPRESSION; BINDING; MODEL; NEUROINFLAMMATION; RADIOTRACERS; AFFINITY; F-18-GE-180; TSPO; Glioma; Grading; Molecular genetics |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Psychiatrie und Psychotherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Mar 2021 07:59 |
| Last Modified: | 23 Mar 2021 07:59 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44504 |
Actions (login required)
 |
View Item |
